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Time-Dependent
Clearance Decrements
of Fluvoxamine in
Depressed Inpatients
A Clinical Evaluation
To the Editors:
The selective serotonin reuptake
inhibitor, fluvoxamine, is used in the
treatment of depressive and anxiety
disorders. Fluvoxamine is well absorbed
after oral administration. Because of
rapid and extensive hepatic first-pass
biotransformation, the amount of un-
changed drug reaching the systemic
circulation is approximately 53%. The
plasma protein binding is low (77%).
The mean half-life is 15 hours.1
In a case report of fluvoxamine
intoxication, in which fluvoxamine con-
centrations were followed for 1 week,
nonlinearity was present at serum levels
of more than 150 ng/mL.2 This plasma
concentration is well inside the range of
steady-state concentrations reached af-
ter therapeutic dosages.3 In a study with
10 healthy volunteers, fluvoxamine was
administered in increasing doses.4 In
this study, fluvoxamine also exhibits
time-dependent kinetics within the dose
range of 25 mg/d during the first week,
with increasing dosage per week until
200 mg/d in the fourth week. This
nonlinear increase is significantly more
pronounced in men than in women with
subtherapeutic dosages.5
This indicates that there can be a
considerable variability in plasma levels
relative to the treatment dose. As the
dose increases, the plasma level of flu-
voxamine increases more than would be
predicted from the lower dose. Because
only limited data are available on the
pharmacokinetics of fluvoxamine in de-
pressed patients, we calculated fluvox-
amine dose to fluvoxamine plasma
concentrations as ratios for each patient
participating in a double-blind trial with
fluvoxamine after attaining a predefined
plasma level.6 Plasma levels of fluvox-
amine were obtained weekly during this
trial. If the plasma level increases more
compared with the dosage, the ratios over
time would change accordingly, and time-
dependent steady-state plasma concentra-
tions were assumed to be present.
The study was performed at the
department of Psychiatry of the Erasmus
Medical Center in Rotterdam (EMCR).
Patients participated in a double-blind,
randomized, controlled trial comparing
fluvoxamine with imipramine after a
single-blind placebo run-in period of 4
days.6 Dosages of drugs prescribed for
somatic indication were optimized be-
fore the trial and remained at the same
dosage during the trial. The smoking
habits of the patients were not assessed;
the smoking habits of the patients re-
mained unchanged during this study.
Included were patients aged 18 to 65
years who had a Diagnostic and Statis-
tical Manual of Mental Disorders,
Fourth Edition diagnosis of depressive
disorder and a Hamilton Rating Scale for
Depression score of 17 or higher.7
Starting with 75 mg, tablets of
fluvoxamine were administered once a
day at 10 PM. After 2 days, the dose was
doubled unless severe side effects were
observed. The pharmaceutical laboratory
of the EMCR monitored blood levels
once a week. Blood samples were
collected 12 hours after the last evening
dose. The hospital pharmacist advised on
the adjustment of the dosage based on
the targeted plasma level according to a
predefined dosage table. This was com-
municated to the treating physician in
percentages to prevent unblinding. The
treating physicians were not involved in
the ratings of this study. Doses of fluvox-
amine were adjusted to obtain predefined
plasma levels. The predefined plasma
level for fluvoxamine was 150 to 200
ng/mL (100% equals 175 ng/mL).8
Fluvoxamine plasma concentra-
tions were measured using a high-
performance liquid chromatographic
method with ultraviolet detection at
260 nm. Fluvoxamine and internal stan-
dard amitriptyline were extracted from
1 mL plasma by using Bond Elut TCA
columns (Varian, Middelburg, The Neth-
erlands). After application of the plasma,
the column was washed with 1 mL
acetonitrile (20% vol/vol), and fluvox-
amine and internal standard were eluted
with 600 AL 0.6% (wt/vol) diethylamine
inmethanol. The eluatewas evaporated to
dryness under nitrogen. Finally, the re-
sidue was reconstituted in 300 AL of
mobile phase ([480mL 0.01M phosphate
buffer + 4 mL butylamine + phosphoric
acid 85% to pH7.3] + 300mLmethanol +
220 mL acetonitrile), and a sample of
100 AL was injected into the analytical
column (ChromSpher, Varian). The limit
of quantification for fluvoxamine was
10 ng/mL. In the range of 50 to 300ng/mL,
interassay and intra-assay coefficients of
variation were less than 5%.
Outcome was assessed 4 weeks
after attaining these predefined plasma
levels. If patients achieved remission,
fluvoxamine and the weekly monitoring
of the plasma level continued until dis-
charge. Concurrent psychotropic drugs
were not allowed except for 1 to 6
tablets a day containing 45 mg of an
extract of valerian in case of severe
anxiety or insomnia; this extract was
assumed to be without antidepressant
effect. According to the protocol, in ex-
ceptional cases, lorazepam (1–3 mg/d
for intolerable anxiety) or haloperidol
(1–10 mg/d in case of intolerable psy-
chotic symptoms) was allowed. A re-
search nurse systematically assessed side
effects.
Time dependency of steady-state
plasma concentrations of fluvoxamine
was assumed to be present if a positive
time trend of ratios between steady-
state plasma concentrations and fluvox-
amine doses could be demonstrated. All
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plasma levels and doses available after
attaining the first predefined adequate
plasma level for all patients were used
for the statistical analysis of the kinet-
ics. Using a random coefficients model,
we tested against an average linear trend
in time (measured in weeks) of the
logarithm of these ratios. Our model is
described as the logarithm of the ratio that
is the intercept or the first plasma level
with addition of a coefficient of the slope
times weeks and, additionally, a residue
(log[ratio] = a + b  weeks + residue).
The intercept and slope with time were
assumed to be randomly (normally)
distributed between patients. Sex was
included in the model as a fixed factor
allowing the testing of the modification
by sex of the slope with time. The within-
patients residual term was assumed to
have a week-to-week autocorrelation
according to a first-order autoregressive
structure. Statistical significance was
defined as P < 0.05. For evaluating the
random coefficient model, SAS version
8 (PROC MIXED) was used.
The ethics committee of the EMCR
approved the protocol. The protocol was
carried out in accordance with the ethical
standards laid down in the Declaration of
Helsinki.
The mean time to reach the pre-
defined plasma levels was 12.6 days
(SD, ±6.2 days; range, 4–33 days) for
fluvoxamine. The mean daily dose dur-
ing the 4 weeks after attaining the first
predefined plasma level for fluvoxamine
was 287.5 mg/d (SD, ±265.8 mg/d; range,
150–800 mg/d), with a mean plasma level
of 215.0 ng/mL (SD, ±39.98 ng/mL;
range, 108.6–325.0 ng/mL). The number
of patients was 39, of whom 80% were
women (n = 31), mean age was 49 years
(SD, ±17 years), and range was 34 to
65 years. The maximum number of weeks
to estimate the ratio between steady-state
plasma levels and doses of fluvoxamine
was 23weeks; themean numbers of weeks
was 11.5 (SD, ±6.93). The average dosage
during this period for the participating
patients (n = 39) was 214.6 mg/d (SD,
±153.77 mg/d); the average plasma level
was 186.0 ng/mL (SD, ±70.38 ng/mL).
On average, the ratio of steady-
state plasma levels to doses of fluvox-
amine increased by 2.2% per week (95%
confidence interval [CI], 1.3–3.1; P <
0.0001) across both sexes. In men, this
was 3.5% (95% CI, 1.3–5.6; P =
0.002), and in women, this was 1.7%
(95% CI, 1.2–2.2; P < 0.0001); the
difference between the sexes was not
significant (P = 0.12).
Figure 1 shows the mean ob-
served ratios of the plasma level com-
pared with the dosage per week. We
back-transformed the logarithm of the
ratios as predicted by our model and
also plotted these results in Figure 1.
DISCUSSION
This is the first study that dem-
onstrates that time-dependent kinetics
of fluvoxamine occur in depressed inpa-
tients observed during an average peri-
od of 11 weeks. An earlier study used
healthy subjects with weekly dosage
increments from 25 up to 200 mg/d
during 4 weeks without reaching steady
state.4
The present study demonstrates
that the fluvoxamine dosage has to de-
crease to attain the used predefined
plasma level range used in this study.
The logarithm of the ratios of plasma
level with fluvoxamine dosage increased
by 2.2% per week during an average
period of 11 weeks. In our population,
we could not detect a plateau phase to
this increment; a longer period of mea-
surement may be needed to establish the
existence of a plateau phase. The mean
plasma level during the 4 weeks after
attaining the first predefined plasma
level for fluvoxamine was 215.0 ng/mL
(SD, ±39.98 ng/mL; range, 108.6–325.0
ng/mL). This level was well outside the
predefined range of 150 to 200 ng/mL.
The latter can be due to the difficulty
of dosing a drug with time-dependent
pharmacokinetics.
The study also shows that the
dose of fluvoxamine has to be relatively
high to obtain the targeted plasma level
compared with average dosages used in
clinical practice and research. This was
also clinically shown in a trial in which
FIGURE 1. The mean observed ratios ((mg/day)/(ng/mL)) of fluvoxamine dose
(mg/day) to fluvoxamine plasma concentrations (ng/mL) per week (solid line) and
the predicted logarithmic ratio (dotted line), using all the plasma levels obtained
during the trial.
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high dosages of fluvoxamine were ef-
fective in the treatment of psychotic
depressed patients.9 The reason for
time-dependent clearance of fluvox-
amine before reaching a steady state
can be nonlinearity. This nonlinearity is
not the Michaelis-Menten saturation
kinetics of a single metabolic pathway,
but a more complex metabolic picture
involving multiple pathways.4
Because marked sex differences
in pharmacokinetics were found (with
women developing higher plasma con-
centrations), we estimated the ratios for
both sexes. No significant difference in
ratio was found. This could be due to the
sex difference being shown to exist at a
dosage of 100 mg/d and disappeared
after the dosage was doubled.5 Our
dosages were mostly far more than
100 mg/d, and this could have influ-
enced the nonsignificant difference in
ratio between men and women. The
disappearance of the difference in phar-
macokinetics between men and women
at a higher dosage suggests the partici-
pation of a saturable enzyme that is
more active in male than in female
subjects. Two studies have reported
that a higher plasma concentration of
fluvoxamine is associated with more
adverse effects.3,4 Techniques to im-
prove individual dosing should provide
the means to decrease the incidence of
side effects and increase the response
rates. These techniques should involve
plasma level determination over an ex-
tended period of treatment considering
that steady-state plasma concentrations
of fluvoxamine are time-dependent. It is
not clear, however, which plasma levels
should be aimed at because data on the
relation between plasma levels and effect
are scarce.8,10 In this respect, the range
for a maximum response with fluvox-
amine of 160 to 220 ng/mL reported by
Foglia et al8 may prove to be useful.
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